Journal of Genetic Syndromes & Gene Therapy
ISSN: 2157-7412
OPEN ACCESS Freely available online
Perspective

# Genotype-Phenotype Correlations in Fragile X Syndrome

**Nikolay Petrov***

*Department of Clinical Laboratory, Cyril and Methodius University, Skopje, Bulgaria*

## DESCRIPTION

Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and a leading monogenic cause of Autism Spectrum Disorder (ASD). It is an X-linked dominant disorder primarily caused by mutations in the *FMR1* gene located at Xq27.3. The disorder is characterized by a range of clinical manifestations including cognitive impairment, developmental delays, behavioral problems, and distinct physical features. The nature and severity of these manifestations vary widely among individuals, and research over the past few decades has increasingly focused on understanding the correlations between specific genotypic variations and phenotypic outcomes. These genotype-phenotype relationships are critical for improving diagnostic precision, prognosis, and individualized care strategies.

The *FMR1* gene encodes the Fragile X Mental Retardation Protein (FMRP), which plays a crucial role in synaptic function and neural development. The pathogenic mechanism in most individuals with FXS is a CGG trinucleotide repeat expansion in the 5′ untranslated region of the *FMR1* gene. In unaffected individuals, the CGG repeat number typically ranges from 5 to 44. A premutation is defined by 55 to 200 repeats, while a full mutation involves more than 200 repeats. Full mutations lead to hypermethylation of the *FMR1* promoter, resulting in transcriptional silencing of the gene and absence or severe reduction of FMRP. The loss of FMRP disrupts synaptic plasticity and regulation of neuronal protein synthesis, contributing to the neurodevelopmental deficits characteristic of FXS.

Phenotypically, individuals with FXS commonly exhibit intellectual disability, with IQ levels typically ranging from moderate to severe in males and mild to moderate in females. Behavioral features may include hyperactivity, social anxiety, gaze aversion, repetitive behaviors, and features overlapping with ASD. Physical traits often associated with FXS include a long face, large ears, hyperextensible joints, and macroorchidism in post-pubertal males. However, the phenotypic expression can vary considerably, especially among females due to X-inactivation and among individuals with mosaicism or incomplete gene silencing. One of the key aspects of genotype-phenotype correlation in FXS lies in the degree of CGG expansion and the methylation status of the *FMR1* gene. Individuals with full mutations and complete methylation generally have more severe intellectual and behavioral impairments due to the absence of FMRP. However, those with mosaicism-where some cells carry a full mutation and others carry a premutation or unmethylated full mutation-tend to present with milder phenotypes. Similarly, individuals with an unmethylated full mutation may still produce small amounts of FMRP, which can mitigate some clinical symptoms.

Another layer of complexity arises in premutation carriers. While they do not typically show the classical symptoms of FXS, premutation carriers are at risk for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in older males and Fragile X-Associated Primary Ovarian Insufficiency (FXPOI) in females. These conditions are believed to result from toxic gain-of-function effects due to elevated *FMR1* mRNA levels rather than a deficiency of FMRP. This underscores the importance of not only measuring CGG repeat number but also analyzing mRNA levels and methylation status for comprehensive genotype assessment.

Sex differences also influence the genotype-phenotype relationship. Because FXS is X-linked, males with full mutations are generally more severely affected than females, who have a second normal X chromosome that may partially compensate for the mutation. The pattern of X-inactivation in females significantly impacts phenotype expression; skewed inactivation favoring the normal allele can result in milder cognitive and behavioral impairments.

Recent advances in molecular diagnostics, including methylation-specific PCR and Southern blot analysis, have enhanced the ability to detect different *FMR1* mutation states and predict phenotypic outcomes. In parallel, neuroimaging studies and functional assessments have begun to link specific brain abnormalities with *FMR1* mutation types, offering new insights into how genotypic variation shapes neural development and behavior.

**Correspondence to:** Nikolay Petrov, Department of Clinical Laboratory, Cyril and Methodius University, Skopje, Bulgaria, E-mail: nikolay.petrov@bgfiction.bg

**Received:** 03-Mar-2025, Manuscript No. JGSGT-25-38592; **Editor assigned:** 05-Mar-2025, PreQC No. JGSGT-25-38592 (PQ); **Reviewed:** 19-Mar-2025, QC No. JGSGT-25-38592; **Revised:** 26-Mar-2025, Manuscript No. JGSGT-25-38592 (R); **Published:** 02-Apr-2025, DOI: 10.35248/2157-7412.25.16.449

**Citation:** Petrov N (2025). Genotype-Phenotype Correlations in Fragile X Syndrome. J Genet Syndr Gene Ther. 14:449.

## CONCLUSION

Fragile X Syndrome presents with a complex interplay between genetic mutation, epigenetic regulation, and individual biological factors that shape its clinical expression. Genotype-phenotype correlations, particularly involving CGG repeat size, methylation status, mosaicism, and sex, provide valuable guidance for diagnosis, prognosis, and management. Continued research into the molecular underpinnings of FXS will not only improve care for affected individuals but may also inform therapeutic strategies targeting the downstream consequences of *FMR1* dysregulation.